

I claim:

1. An immunological composition comprising two, three, or four distinct protein-polysaccharide conjugates, wherein each of the conjugates comprises a capsular polysaccharide from two or more serogroup of *N. meningitidis* conjugated to one or more a carrier protein(s).
2. The immunological composition of claim 1, wherein the capsular polysaccharides are selected from the group consisting of capsular polysaccharides from serogroups A, C, W-135 and Y of *N. meningitidis*
3. The immunological composition of claim 1, wherein the capsular polysaccharides are from serogroups A and C of *N. meningitidis*.
4. The immunological composition of claim 1, wherein the capsular polysaccharides are from serogroups A, C, W-135 and Y of *N. meningitidis*.
5. The immunological composition of claim 1, wherein the carrier protein is diphtheria toxoid.
6. The immunological composition of claim 1, further comprising an adjuvant.
7. The immunological composition of claim 5, wherein the adjuvant is aluminum hydroxide.
8. The immunological composition of claim 5, wherein the adjuvant is aluminum phosphate.
9. A method of inducing an immunological response to capsular polysaccharide of *N. meningitidis* comprising administering an immunologically effective amount of the immunological composition of claim 1 to a human or animal.
10. A multivalent meningococcal vaccine comprised of immunologically effective amounts of from two to four distinct protein-polysaccharide conjugates, wherein each of the conjugates contains a different capsular polysaccharide conjugated to a carrier protein, and wherein each capsular polysaccharide is selected from the group consisting of capsular polysaccharide from serogroups A, C, W-135 and Y.

11. The multivalent meningococcal vaccine of claim 9, wherein the capsular polysaccharides are prepared from serogroups A and C of *N. meningitidis*.
12. The multivalent meningococcal vaccine of claim 9, wherein the capsular polysaccharides are prepared from serogroups A, C, W-135 and Y of *N. meningitidis*.
13. The multivalent meningococcal vaccine of claim 9, wherein the carrier protein is diphtheria toxoid.
14. The multivalent meningococcal vaccine of claim 9, further comprising an adjuvant.
15. The multivalent meningococcal vaccine of claim 13, wherein the adjuvant is aluminum hydroxide.
16. the multivalent meningococcal vaccine of claim 13, wherein the adjuvant is aluminum phosphate.
17. A method of protecting a human or animal susceptible to infection from *N. meningitidis* comprising administering to the human or animal an immunologically effective amount of the vaccine of claim 9.